1. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
- Author
-
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland KE, Doshi JA, and Huntington SF
- Subjects
- Humans, Aged, United States epidemiology, Rituximab therapeutic use, Health Resources, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Retrospective Studies, Medicare, Lymphoma, Large B-Cell, Diffuse drug therapy
- Abstract
Aim: To examine real-world treatment patterns, survival, healthcare resource use and costs in elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL). Methods: 11,880 Medicare patients aged ≥66 years with DLBCL between 1 October 2015 and 31 December 2018 were followed for ≥12 months after initiating front-line treatment. Results: Two-thirds (61.2%) of the patients received standard-of-care R-CHOP as first-line treatment. Hospitalization was common (57%) in the 12-months after initiation of 1L treatment; the mean DLCBL-related total costs were US$84,416 during the same period. Over a median follow-up of 2.1 years, 17.8% received at least 2L treatment. Overall survival was lower among later lines of treatment (median overall survival from initiation of 1L: not reached; 2L: 19.9 months; 3L: 9.8 months; 4L: 5.5 months). Conclusion: A large unmet need exists for more efficacious and well-tolerated therapies for older adults with DLBCL.
- Published
- 2024
- Full Text
- View/download PDF